CATALYST PHARMACEUTICA

Catalyst Pharmaceuticals Reports Strong Second Quarter 2023 Financial Results and Provides Corporate Update

09 8 2023 15:17:05 提供 Nasdaq GlobeNewswire

Catalyst Pharmaceuticals Acquires Exclusive North American License For Vamorolone for Duchenne Muscular Dystrophy from Santhera Pharmaceuticals

19 7 2023 05:00:00 提供 Nasdaq GlobeNewswire

Catalyst Pharmaceuticals to License North American Rights to Vamorolone for Duchenne Muscular Dystrophy from Santhera Pharmaceuticals

20 6 2023 05:00:00 提供 Nasdaq GlobeNewswire

Catalyst Pharmaceuticals Reports Positive Momentum in Second Quarter 2023

01 6 2023 07:03:00 提供 Nasdaq GlobeNewswire

Catalyst Pharmaceuticals Appoints Tamar Thompson to its Board of Directors

30 5 2023 07:03:00 提供 Nasdaq GlobeNewswire

Catalyst Pharmaceuticals Reports Record First Quarter 2023 Results, Achieving 98% Total Revenue Growth Year-over-Year

10 5 2023 15:28:05 提供 Nasdaq GlobeNewswire

Catalyst Pharmaceuticals Advances sNDA Submission Plans To Increase Indicated Maximum Dose For FIRDAPSE® From 80 mg Per Day To 100 mg Per Day

09 5 2023 07:03:00 提供 Nasdaq GlobeNewswire

Catalyst Pharmaceuticals Announces Release of Inaugural ESG Report

01 5 2023 07:03:00 提供 Nasdaq GlobeNewswire

Catalyst Pharmaceuticals to Report First Quarter 2023 Financial Results on May 10, 2023

24 4 2023 07:03:00 提供 Nasdaq GlobeNewswire

Catalyst Pharmaceuticals Announces Third-Party Abstracts on FYCOMPA® (Perampanel) to be Presented at the Upcoming American Academy of Neurology 2023 Annual Meeting

20 4 2023 07:03:00 提供 Nasdaq GlobeNewswire

Catalyst Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

15 3 2023 15:11:45 提供 Nasdaq GlobeNewswire

Catalyst Pharmaceuticals Announces a Recent Third-Party Publication in Peer-Reviewed Journal Epilepsia Showing Perampanel (FYCOMPA®) Demonstrated High Efficacy in Patients with Rare Genetic Epilepsies

08 3 2023 10:20:58 提供 Nasdaq GlobeNewswire

Catalyst Pharmaceuticals to Report Fourth Quarter and Full-Year 2022 Financial Results on March 15, 2023

01 3 2023 07:03:00 提供 Nasdaq GlobeNewswire

Catalyst Pharmaceuticals to Ring the Nasdaq Closing Bell in Honor of International Rare Disease Day

22 2 2023 07:03:00 提供 Nasdaq GlobeNewswire

Catalyst Pharmaceuticals Reports Preliminary Fourth Quarter and Full Year 2022 Total Revenues and Provides Full Year 2023 Revenue Guidance

07 2 2023 07:03:00 提供 Nasdaq GlobeNewswire

Catalyst Pharmaceuticals Completes the Acquisition of U.S. Rights to FYCOMPA® (Perampanel) CIII

25 1 2023 07:03:00 提供 Nasdaq GlobeNewswire

Catalyst Pharmaceuticals Comments on FDA's Announcement of its Position on Orphan Drug Exclusivity In Light of the 11th Circuit Decision in Catalyst Pharmaceuticals, Inc. v. Becerra

23 1 2023 12:25:09 提供 Nasdaq GlobeNewswire

Catalyst Pharmaceuticals Notified of Abbreviated New Drug Application Filing for FIRDAPSE®

23 1 2023 07:03:00 提供 Nasdaq GlobeNewswire

Catalyst Pharmaceuticals to Acquire U.S. Commercial Rights to FYCOMPA® (Perampanel) CIII From Eisai Co., Ltd

19 12 2022 15:10:00 提供 Nasdaq GlobeNewswire

Catalyst Pharmaceuticals Reports Record Third Quarter 2022 Financial Results and Provides a Corporate Update

09 11 2022 15:11:31 提供 Nasdaq GlobeNewswire